Source: https://cyberleninka.ru/article/n/pseudomonas-aeruginosa-lectins-as-targets-for-novel-antibacterials
Timestamp: 2019-04-25 22:15:54+00:00

Document:
Аннотация научной статьи по медицине и здравоохранению, автор научной работы — Grishin A. V., Krivozubov M. S., Karyagina A. S., Gintsburg A. L.
Pseudomonas aeruginosa is one of the most widespread and troublesome opportunistic pathogens that is capable of colonizing various human tissues and organs and is often resistant to many currently used antibiotics. This resistance is caused by different factors, including the acquisition of specific resistance genes, intrinsic capability to diminish antibiotic penetration into the bacterial cell, and the ability to form biofilms. This situation has prompted the development of novel compounds differing in their mechanism of action from traditional antibiotics that suppress the growth of microorganisms or directly kill bacteria. Instead, these new compounds should decrease the pathogens’ ability to colonize and damage human tissues by inhibiting the virulence factors and biofilm formation. The lectins LecA and LecB that bind galactose and fucose, as well as oligoand polysaccharides containing these sugars, are among the most thoroughly-studied targets for such novel antibacterials. In this review, we summarize the results of experiments highlighting the importance of these proteins for P. aeruginosa pathogenicity and provide information on existing lectins inhibitors and their effectiveness in various experimental models. Particular attention is paid to the effects of lectins inhibition in animal models of infection and in clinical practice. We argue that lectins inhibition is a perspective approach to combating P. aeruginosa. However, despite the existence of highly effective in vitro inhibitors, further experiments are required in order to advance these inhibitors into pre-clinical studies.
2016 / Batishcheva G.A., Malorodova T.N., Pokrovskaya T.G., Kazakova E.E., Urojevskaya J.S., Zhernakova N.I., Osipova O.A.
2013 / Стибель В.В., Сварчевський О.А., Антонюк В.О., Закальська О.М., Гончар М.В.
2016 / Malorodova T.N., Pokrovskaya T.G., Kazakova E.E., Urojevskaya J.S.
2016 / Yakimova E.A., Laishevtcev A.I., Kapustin A.V., Lenev S.V., Motorygin A.V., Kuteynikova N.S.
Copyright © 2015 Park-media, Ltd. This is an open access article distributed under the Creative Commons Attribution License,which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
ABSTRACT Pseudomonas aeruginosa is one of the most widespread and troublesome opportunistic pathogens that is capable of colonizing various human tissues and organs and is often resistant to many currently used antibiotics. This resistance is caused by different factors, including the acquisition of specific resistance genes, intrinsic capability to diminish antibiotic penetration into the bacterial cell, and the ability to form biofilms. This situation has prompted the development of novel compounds differing in their mechanism of action from traditional antibiotics that suppress the growth of microorganisms or directly kill bacteria. Instead, these new compounds should decrease the pathogens' ability to colonize and damage human tissues by inhibiting the virulence factors and biofilm formation. The lectins LecA and LecB that bind galactose and fucose, as well as oligo- and polysac-charides containing these sugars, are among the most thoroughly-studied targets for such novel antibacterials. In this review, we summarize the results of experiments highlighting the importance of these proteins for P. ae-ruginosa pathogenicity and provide information on existing lectins inhibitors and their effectiveness in various experimental models. Particular attention is paid to the effects of lectins inhibition in animal models of infection and in clinical practice. We argue that lectins inhibition is a perspective approach to combating P. aeruginosa. However, despite the existence of highly effective in vitro inhibitors, further experiments are required in order to advance these inhibitors into pre-clinical studies.
KEYWORDS Pseudomonas aeruginosa, lectin, LecA, LecB, antibiotic resistance, biofilm, inhibitor. ABBREVIATIONS IPTG - isopropyl-P-D-thiogalactopyranoside; PQS - Pseudomonas quinolone signal; IFN-y -interferon-y; Lea, Lex - Lewis oligosaccharides; TNFa - tumor necrosis factor a; ITC - isothermal titration calo-rimetry; ELLA - enzyme-linked lectin assay; SPR - surface plasmon resonance.
insufficient chloride canal function and mucus accumulation in lungs, reducing the lung function and the patient's life expectancy .
films are organized microbial communities submerged into the extracellular polymer matrix, which consists of polysaccharides, proteins, and DNA synthesized by these microorganisms [3, 4]. Inside biofilm, bacteria become significantly more resistant to unfavorable environmental conditions, as well as to antimicrobial agents and factors of the human immune system . P. aeruginosa forms difficult-to-remove biofilms in patients' organs and tissues, as well as on implanted devices and catheters [3, 5]. One of the popular approaches to solving this problem suggests the design of new substances that would either inhibit or inactivate the virulence factors of pathogenic bacteria (toxins, adhesins, effector proteins modulating the metabolism and the immune response of the host organism, secretion systems delivering these proteins to the target site, and factors facilitating communication between the bacteria and biofilm formation) rather than kill the pathogens by inhibiting their biosynthesis . In other words, the strategy consists in disarming rather than killing the pathogen. Resistance to these antivirulent compounds is expected to develop in slower fashion, since they will not have a direct effect on bacterial viability but will only affect their ability to infect humans.
inosa biofilms, thus acting as key virulence factors. In this review, we have summarized the results of studies focused on the role of lectins LecA and LecB in the pathogenesis and formation of biofilms, described currently known inhibitors of these proteins, and assessed the potential for using these proteins as targets to treat infections caused by P. aeruginosa.
Lectins LecA and LecB (also commonly known as PA-IL and PA-IIL) were isolated from P. aeruginosa in the 1970s as proteins capable of agglutinating human and animal erythrocytes [7-9]. Both lectins are small proteins 121 (LecA) and 115 (LecB) amino acid residues in size (12.8 and 11.9 kDa, respectively) [10, 11]. LecA binds D-galactose and, with lower affinity, N-acetyl-D-galactosamine. L-fucose exhibits the highest affinity to LecB, but this lectin also binds mannose and a number of other saccharides. Although LecA and LecB have completely different amino acid sequences, their quaternary structures are similar: both lectins form homotetrameric complexes where each monomer has its own ligand-binding site. Thus, a single tetramer can bind four molecules of the corresponding carbohydrate [12, 13] (Fig. 1). In Pseudomonas genus, the lecA and lecB genes are unique to P. aeruginosa; however, homologs are found in such bacteria as Burkholderia and Photorhabdus.
domonas quinolone signal (PQS), components of the quorum sensing system [14, 15]. The function of this system is based on the release of low-molecular-weight substances of different natures by these bacteria (in particular, acyl homoserine lactones and quinolones), which allows them to send signals about their presence to other bacteria. That is how bacteria "feel" that a certain population density level has been reached and trigger the expression of virulence factors (such as LasA and LasB proteases, exotoxin A, alkaline protease, etc.) and biofilm formation . The regulation of LecA expression is very similar to the regulation of the synthesis of pyocyanin, an important toxin inducing oxidative stress and damage to the cells of the host organism [14, 15, 17-20]. Interestingly, the level of produced LecA, as well as other virulence factors, increases when the pathogen comes into contact with certain molecules produced by the host organism under stress conditions: noradrenalin, IFN-y, adenosine, and x-opioid peptide dynorphin [19, 21-23].
OprF and is not detected on the membrane of bacteria with mutations in the oprF gene . However, taking into account the fact that these mutations significantly change the overall properties of the P. aeruginosa outer membrane , it is not inconceivable that other proteins can also be involved in anchoring LecB to the membrane. As opposed to LecB, localization of LecA remains virtually unstudied.
The role of lectins LecA and LecB in the pathogene-sis of the diseases accompanying a P. aeruginosa infection is not yet unambiguously determined. Some data demonstrate that these lectins enhance adhesion of the bacteria to the substrate (e.g., human cells), are involved in the aggregation of bacterial cells, biofilm formation, and interaction between a bacterium and the host organism's tissues, resulting in tissue damage. The presumed role of lectins has been schematically summarized in Fig. 2.
LecA and LecB lectins bind the oligosaccharides of many human and mammalian glycoproteins [28-34], thus naturally suggesting that lectins are directly involved in the adhesion of P. aeruginosa to human tissues . Adhesion is a crucial stage in pathogenesis.
Adhesion of bacterial cells to the epithelial tissue surface precedes colonization, which may subsequently lead to biofilm formation or pathogen invasion. However, the experimental data on the role of LecA and LecB lectins in P. aeruginosa adhesion are controversial. Wentworth et al.  studied bacterial adhesion to a rabbit corneal epithelium culture. Addition of bacterial cell lysate was shown to increase the amount of adhered intact bacteria; this effect was partially inhibited by addition of galactose, mannose, and fucose. A conclusion was drawn that stimulation of adhesion is associated with the release of lectins from the cytoplasm of the lysed bacterial cells. Binding of bacteria to fibronectin, one of the most common human glyco-proteins, was also inhibited by addition of saccharides: to the greatest extent, by adding sialic acid, N-acetyl-glucosamine and N-acetylgalactosamine and to a lower extent, by adding galactose and fucose . However, as opposed to the previous study, addition of LecA did not increase but reduced the amount of bacterial cells bound to immobilized fibronectin. P. aeruginosa strains with mutations in the lecA and lecB genes retain their ability to bind to mucins (glycoproteins secreted by epithelial cells) , while their ability to bind to A549 human lung epithelial cells significantly deteriorates [39, 40]. It was also demonstrated that binding to A549 cells is inhibited in a dose-dependent manner by lectin ligands, methyl-P-galactoside and methyl-a-fucoside , while binding to immortalized human airway epithelial cells NuLi (derived from a healthy donor) and CuFi (derived from a cystic fibrosis patient) is inhibited by the addition of anti-LecB antibodies, but not control non-specific antibodies . Contrariwise, Eierhoff et al.  demonstrated that interaction between lectin LecA and globotriaosilceramide (Gb3) is required for the invasion of P. aeruginosa inside H1299 human lung epithelial cells and inside artificial vesicles but plays no role in adhesion. Bacteria with mutation in the lecA gene bind to H1299 cells and artificial vesicles with the same efficiency as wild-type bacteria do. These contradictions probably arose from the fact that different substrates were used to study adhesion (isolated gly-coproteins, epithelial cells of different origin) and on whether lectins had an effect on the binding to a certain substrate or did not depend on the range of oligo-saccharides present on the substrate surface.
It should also be mentioned that in addition to lec-tins, P. aeruginosa adhesion to the cells of a host organism is also ensured by other factors, such as flagella and type IV pili [43, 44]. It is rather difficult to distinguish between the effects arising from the presence of different adhesins. Furthermore, it is known that functional LecB is required to ensure normal assembly of P. aeruginosa pili and secretion of certain proteins .
Hence, although P. aeruginosa lectins play a crucial role in binding the pathogen to certain types of human cells, the mechanism underlying this process has not been fully elucidated; its role in in vivo infection remains uncertain; and the contribution of lectins in it can be either direct (interaction with glycan structures on the cell surface) or indirect (involvement in assembly, secretion, and functioning of other adhesins, such as type IV pili).
Both lectins are involved not only in adhesion, but also in the formation of P. aeruginosa biofilms. Independent research groups have used different experimental models to demonstrate that P. aeruginosa strains with mutations in the lecA and lecB genes form poorly developed biofilms without the well-defined architecture that is typical of the biofilms of wild-type strains [25, 38, 45, 46]. Furthermore, addition of isopropyl-P-D-thiogalactopyranoside (IPTG) or nitrophenylgalac-toside (galactose derivatives capable of binding to LecA with a higher affinity than galactose) when P. aerugi-nosa biofilms were grown on steel coupons inhibited biofilm formation to the level of the lecA mutant (the surface area of the biofilm was twice as low compared to that of wild-type biofilms grown without IPTG), while addition of galactosides to the already formed biofilms resulted in their dispersal. It is noteworthy that galactosides affected neither formation nor dispersal of the biofilm formed by the strain with a mutation in the lecA gene . Identically, biofilms formed by P. aeruginosa with mutations in the lecB gene on cover slips were much thinner and had a smaller surface area than the wild-type biofilms [25, 46]. Similar to galactosides, LecB ligand nitrophenylfucoside prevented biofilm formation and partially dispersed wild-type biofilms but not those of lecB mutant. It is an interesting fact that nitrophenylfucoside inhibited biofilm formation not only by the laboratory strain PAO1, but also by three clinical isolates .
tentially facilitate the formation of denser biofilms that would be more resistant to physical impact. Interestingly, the extracellular polysaccharide Psl that is absolutely required for the formation of P. aerugi^sa biofilms contains mannose and, according to some sources, galactose, which are ligands of lectins LecB and LecA, respectively [47, 48]. Binding of this polysaccharide to bacterial cells is required to initiate the biofilm formation process .
The direct effect of lectins on human airway and intestinal epithelial cells was investigated in several studies. It has been demonstrated that addition of LecA significantly slows the growth of nasal polyp epithelial cells and reduces the number of ciliated cells. Furthermore, LecA causes formation of large vacuoles in the cells and, when added at large concentrations, even cell detachment . Incubation with LecA also significantly reduces the ciliary beat frequency [51, 52]. The effect of LecA on the ciliary beat frequency was attenuated by adding D-galactose. Ciliary beat was inhibited by LecB, and this effect was attenuated by adding fu-cose [51-54]. In the norm, movements of airway epithelium ciliated cells facilitate the removal of mucus and foreign particles trapped by it (including bacterial cells) from the lungs. Inhibition of the ciliary function is most likely to be caused by binding of lectins to glycoproteins on the surface of epithelial cells and the response of epithelial cells to this event or directly by cilia cross-linking to one another . However, these effects have been demonstrated only in in vitro models and it remains unclear how important they are in an airway infection in vivo.
lium permeable to endotoxin A, which enters the blood flow.
Lectins perform their functions by binding oligo- and polysaccarides, whether they are human or bacterial glycoprotein oligosaccharides or matrix polysaccha-rides of P. aeruginosa biofilms. Specificity of lectins with respect to the saccharides being bound plays the key role in this process.
Lectin LecA preferentially binds to a-D-galactose and oligo- and polysaccharides containing terminal non-reducing residues of a-D-galactose, such as the B, Pk and Pj blood group antigens, melibiose and ga-lactobiose, plant-derived galactomannans, etc. [28-30, 57]. Similar to many other lectins, the galactose-bind-ing site of LecA contains a calcium ion bound to protein carboxyl groups via coordination bonds. The galactose molecule is present in the binding site in its most stable 4C: conformation; the O3 and O4 atoms are involved in coordination bonds with an immobilized calcium ion; the O2, O3, and O4 atoms form additional hydrogen bonds with the amino acid residues of the protein; and the O6 atom forms hydrogen bonds with a water molecule that is firmly fixed by two hydrogen bonds in the binding site [12, 58] (Fig. 3A). The dissociation constant of the LecA-galactose complex is 88 . The terminal residue of a-D-galactose plays the key role in binding of oligosaccharides by lectin LecA, while other oligosaccharide residues form few contacts with the protein [31, 58]. In this connection, the oligosaccha-ride affinity to LecA may vary within a rather narrow range depending on the composition of the oligosac-charide and the details of the glycoside bond connecting the terminal galactose residue to the next residue in the oligosaccharide: the dissociation constants typically vary from 30 to 130 ^M [31, 58]. In addition to a-D-galactose, LecA can also bind N-acetyl-D-galac-tosamine (although with lower affinity) [7, 60], as well as adenine and acyl-homoserine lactones; however, an independent binding site is involved in the latter interaction [61, 62].
yl groups in the equatorial position and one hydroxyl group in the axial position. This fact makes a landmark contribution to LecB specificity: all the saccharides bound by LecB have this arrangement of hydroxyl groups in their most energetically favorable conformations [63, 65]. Like LecA, LecB interacts with oligosac-charides having terminal non-reducing residues of the corresponding monosaccharides, in particular L-fucose. It has been demonstrated that LecB can bind oligosac-charides of the A, B, H, Lea and Lex blood groups [28, 32, 66, 67]. The terminal fucose residue makes the main contribution to the energy of interaction between the oligosaccharides and LecB, although the oligosaccha-ride affinities can be increased 14-fold compared to that of fucose due to the composition and positions of other monosaccharide residues, which has been demonstrated for Lea .
A large number of various LecA and LecB inhibitors have been proposed over the past decade. Except for glycomimetic peptides , all of them contain residues of the corresponding saccharides as affine groups. These inhibitors include monosaccharide derivatives, multivalent glycoclusters and dendrimers of different chemical nature, and natural glycoproteins and poly-saccharides.
saccharides do. For example, even small hydrophobic substituents at the first oxygen atom increase the affinity of the corresponding saccharides both to LecA and LecB. The dissociation constant of the LecA-IPTG complex is almost threefold lower than that of the Le-cA-D-galactose complex [59, 60], while the dissociation constant of the LecB-methyl-a-L-fucoside complex is sevenfold lower than that of the LecB complex with unmodified L-fucose .
aliphatic linker preventing the formation of an CH-n interaction provides for a much lower increase in affinity [68-71].
Lectin LecB does not exhibit such a simple dependence. Among monovalent ligands, oligosaccharide Lea (Table, compound 2) has the greatest affinity to LecB . The Kd of the LecB-Lea complex is 210 nM, while that of the LecB-fucose complex is 2.9 ^M. Although several attempts have been made to design ligands that would exhibit higher affinity than Lea, this objective has not been achieved. Various derivatives of disaccha-ride a-L-Fuc-(1^4)-P-D-GlcNAc - the component of Lea - have been characterized by an affinity to LecB identical to that of Lea. An analysis of the crystalline structure of the complex has demonstrated that the inserted substituents are not involved in the formation of contacts with the protein . A series of fucosylamides have been designed where the first oxygen atom of fucose is replaced with a nitrogen atom of the amide group carrying different appreciably bulky substitu-ents of non-saccharide nature . All the compounds were bound to LecB with dissociation constants of 0.68-2.1 ^M, which shows no improvement compared to Lea and even methylfucoside. The reason is that the amide group cannot interact with the conservative water molecule that participates in the ligand binding to lectin LecB. Finally, Hauck et al.  have designed several classes of derivatives of methyl-D-mannoside, another saccharide that binds to LecB with an affinity lower than that of LecB binding to fucose (Kd = 71 ^M). Some amide and sulfonamide derivatives at the 6th position of mannose show a significant increase in affinity. For example, Kd for one of sulfonamides is 3.3 ^M. Although this value is 20-fold higher compared to the initial methylmannoside, no improvement compared to fucose and Lea was achieved.
Thus, there are no monovalent ligands with an affinity to lectins higher than that of unmodified mono-saccharides by more than an order of magnitude. This is one of the reasons why researchers have focused on designing multivalent inhibitors.
the interaction between lectins and glycans via several mechanisms. First, in some cases several sites of multivalent lectin can simultaneously bind several epitopes of a multivalent ligand. Such interaction is known as a chelate or bridging interaction. Second, even if simultaneous binding is impossible, the presence of several epitopes that can interact with lectin on a single ligand molecule increases the local concentration of these epitopes. During dissociation of the lectin complex with a single epitope, lectin has a high probability of binding to another identical epitope that is located nearby. This mechanism of ligand entrapment is known as statistical rebinding [76, 77]. These effects have recently been used increasingly often to design multivalent compounds inhibiting the effect of lectins: glycoclusters, glycodendrimers, and glycopolymers [76, 78].
ized with galactose residues and gold nanoparticles ; dendrimers of peptide [59, 86] and non-peptide nature [87, 88]; and bivalent compounds [89-91] were proposed for use as multivalent inhibitors of LecA. The LecB inhibitors included synthetic oligomers based on pentaerythrityl phosphodiester , dendrimers based on lysins and cyclopeptides , those based on D- and L-oligopeptides [46, 94, 95], glycoclusters based on tri-thiocyanuric acid  and calixarenes , as well as bi-and trivalent compounds functionalized by disaccha-ride a-L-Fuc-(1^4)-P-D-GlcNAc instead of fucose .
Many of these compounds are characterized by a significantly increased affinity to the corresponding lectin in isothermal titration calorimetry (ITC) experiments and efficiency in inhibition of lectin binding to immobilized saccharides in enzyme-linked lectin assay (ELLA). For example, the Kd values of the complexes of LecA with galactosylated glycoclusters based on cyclic oli-gosaccharides (table, compound 3)  and calixarenes (table, compound 4) , oligopeptide dendrimer (table, compound 7) , and the bivalent ligand selected during screening of a library consisting of 625 compounds (table, compound 9)  were ~ 80-100 nM, which is almost 1,000-fold lower than the Kd of galactose. The bivalent ligand where two galactose residues are connected by a rigid linker ~24 A long is characterized by the highest affinity to LecA; its Kd is 28 nM (table, compound 10) . According to the molecular modeling data, all these ligands can bind two monomers of a LecA tetramer, thus providing a chelate effect, which is probably responsible for such a significant increase in affinity. In the LecB tetramer, the distance between the fucose-binding sites in the adjacent monomers is much greater (~26-28 A in LecA and at least 35-37 A in LecB), and the increase in affinity due to the multiva-lence in LecB inhibitors is significantly lower.
the dispersion of already formed biofilms. Tetravalent glycoclusters based on calixarenes functionalized with galactose and fucose (table, compounds 5 and 6) proved also capable of inhibiting the formation of P. aeruginosa biofilms by PAO1 . Interestingly, these glycoclusters inhibited the biofilm growth not only of the PAO1 strain, but also of the lecA and lecB gene mutants, thus demonstrating that these compounds can potentially affect other targets as well. These glycoclusters inhibited bacterial adhesion to A549 cells by 70 and 90% (gly-cosylated and fucosylated glycoclusters, respectively). The inhibition was more significant compared to that observed when the lecA or lecB genes were inactivated, which also suggests that these compounds may affect other targets. Trivalent glycoclusters based on trithio-cyanuric acid functionalized either by galactose or by fucose (table, compounds 11 and 12) are also capable of inhibiting biofilm formation. Although the affinity of these glycoclusters to the corresponding lectins is significantly lower, their effective concentrations suppressing biofilm formation are the same as those for calixarenes (5 mM). Novoa et al.  demonstrated that the bivalent LecA ligand (table, compound 9) at a concentration of 0.05-5 ^M can prevent the penetration of P. aeruginosa inside H1299 cells by 50-80%, although no dose dependence was revealed.
The ability to bind P. aeruginosa lectins has been revealed not only in chemically synthesized but also in many natural compounds. Unfortunately, most of these compounds have not been isolated into components and only a certain degree of assumption can be made regarding the nature of their active components. Furthermore, their ability to interact with lectins has been typically demonstrated only using hemagglutination assay and western blot hybridization, without the use of more reliable quantitative procedures.
Hemagglutination assay and western blot demonstrated that the proteins of pigeon and quail egg whites [97, 98], components of honey and royal jelly , human breast milk and milk from some other mammals [66, 100], and extracts from the seeds of some edible plants  can interact with P. aerugi-nosa lectins.
ginosa . The action of galactomannan, like that of peptide dendrimers, is probably based on the multiva-lence effect.
The positive effect of inhibition of lectins LecA and LecB has been demonstrated both in in vitro and in vivo experiments: the use of lectin-specific monosac-charides and synthetic inhibitors was studied using animal models of the infection. Furthermore, single cases of using monosaccharides in clinical practice have been reported.
In the aforedescribed experiments on a model of intestinal infection in mice subjected to 30% partial hepatectomy, 107 CFU P. aeruginosa injected into the cecum caused 100% fatality, and so did a combination of lectin LecA and exotoxin A. However, 13% N-acetylgalactosamine added to the injection mixture reduced the fatality rate almost to zero in both cases . The effect of the addition of simple saccharides (lectin ligands) was also observed in a mouse model of lung infection . Intratracheal injection of P. aeru-ginosa PAO1 increased the permeability of lung epithelium and resulted in fluid accumulation in the lungs and bacterial dissemination in the organism. Infection with strains with mutations in the lecA or lecB genes had a much smaller effect on lung permeability and caused lower bacterial dissemination both in the lungs and blood of the infected mice, although their survival rates remained the same compared to mice infected with the wild-type strain. The addition of saccharides binding to LecA (N-acetylgalactosamine and methyl-a-galactoside) or LecB (methyl-a-fucoside) at concentrations of 15-50 mM, but not glucose, reduced the negative effects caused by the injection of bacteria and bacterial dissemination in the lungs and blood. Furthermore, methyl-a-galactose and N-acetylgalactosamine led to a better survival rate among the infected mice. The effectiveness of synthetic lectins inhibitors, tet-ravalent galactosylated, and fucosylated calixarene-based glycoclusters (table, compounds 5 and 6) was studied in the same model of acute lung infection in mice . As might have been expected, glycoclusters showed much higher effectiveness both in retaining the lung barrier function and in reducing the bacterial dissemination in the lungs and spleen compared to monosaccharides at same concentrations (1-5 mM). Lung permeability for labeled albumin after glycoclus-ters had been added was the same as after the injection of strains with mutations in the lectin genes ; the bacterial dissemination in lungs and spleen decreased by 1-3 orders of magnitude. The fucosylated glycoclu-ster was more effective. Unfortunately, no data on the survival rate were available.
Several cases in which saccharide solutions were used to treat a P. aeruginosa infection in humans have also been reported. Steuer et al.  demonstrated the effectiveness of using D-galacose, D-mannose, and sialic acid solutions to treat external otitis caused by infection with P. aeruginosa, although in this case the effect could have been due to inhibition of some other adhesins besides lectins. A case of successful treatment of the upper airway infection in a child subjected to chemotherapy has also been reported . The infection was resistant to antibiotics, while inhalation of galactose and fucose solutions resulted in the complete elimination of the pathogen. Finally, Hauber et al. studied inhalation of solutions of these saccharides to treat cystic fibrosis patients whose lungs were chronically colonized by P. aeruginosa . A twice-daily inhalation of the saccharide solution for 21 days significantly reduced bacterial counts in the patients' sputum and inhibited TNFa expression. Unfortunately, no statistically significant improvement in lung function was observed, which was related to the insufficient sample size.
Although the effect of using monosaccharides in the aforementioned studies was often rather small, recent data have demonstrated that these limitations can be potentially overcome by using multivalent compounds. The results of these studies have convincingly confirmed that positive results can be achieved in vivo by inhibition of P. aeruginosa lectins.
Lectins LecA and LecB seem to be among the virulence factors of P. aeruginosa: they contribute to the ability of this organism to colonize human tissues and organs and persist in them as biofilms, thus causing hard-to-treat chronic diseases. Both lectins affect bacteria's ability to attach to epithelial human cells, are the key components of bacterial biofilms, and can inhibit the ciliary movement and disturb the barrier function of epithelial tissue. Unfortunately, it remains unclear how important each of these lectin functions in in vivo infection is. Taking into account the fact that lectin specificity differs, it cannot be ruled out that P. aeruginosa LecA and LecB play different roles in the infection of a human organism. However, regardless of the nature of lectins function, the use of corresponding monosaccha-rides and multivalent glycoclusters in animal models of a P. aeruginosa infection has reliably demonstrated the positive effect of the inhibition of both lectins, which has also been confirmed by clinical data.
pounds bearing several affine groups can simultaneously bind two monomers from a single tetramer. The molecular modeling method has demonstrated that some compounds potentially possess this ability. It was found that some classes of multivalent compounds can inhibit the development of P. aeruginosa biofilms and/ or impede bacterial adhesion to epithelial cells. The positive effect of tetravalent calixarene-based glyco-clusters in an in vivo acute model of lung infection was also demonstrated.
The authors are grateful to Vera Gusakova for her assistance in preparing illustrations for the manuscript and Anna Ershova for meticulous proofreading and valuable comments. This work was supported in part by the RF President's grant "Leading Scientific Schools" (NSh-2038.2014.7).
1.	Blanc D.S., Petignat C., Janin B., Bille J., Francioli P. // Clin. Microbiol. Infect. 1998. V. 4. № 5. P. 242-247.
2.	Mesaros N., Nordmann P., Plésiat P., Roussel-Delvallez M., van Eldere J., Glupczynski Y., van Laethem Y., Jacobs F., Lebecque P., Malfroot A., et al. // Clin. Microbiol. Infect. 2007. V. 13. № 6. P. 560-578.
3.	Donlan R.M., Costerton J.W. // Clin. Microbiol. Rev. 2002. V. 15. № 2. P. 167-193.
4.	Hall-Stoodley L., Costerton J.W., Stoodley P. // Nat. Rev. Microbiol. 2004. V. 2. № 2. P. 95-108.
5.	Costerton J.W. // Science. 1999. V. 284. № 5418. P. 13181322.
6.	Clatworthy A.E., Pierson E., Hung D.T. // Nat. Chem. Biol. 2007. V. 3. № 9. P. 541-548.
7.	Gilboa-Garber N. // FEBS Lett. 1972. V. 20. № 2. P. 242244.
8.	Gilboa-Garber N., Mizrahi L., Garber N. // Can. J. Bio-chem. 1977. V. 55. № 9. P. 975-981.
9.	Gilboa-Garber N. // Methods Enzymol. 1982. V. 83. № 1980. P. 378-385.
10.	Avichezer D., Katcoff D.J., Garber N.C., Gilboa-Garber N. // J. Biol. Chem. 1992. V. 267. № 32. P. 23023-23027.
11.	Gilboa-Garber N., Katkoff D.J., Garber N.C. // FEMS Immunol. Med. Microbiol. 2000. V. 29. P. 53-57.
12.	Cioci G., Mitchell E.P., Gautier C., Wimmerová M., Suda-kevitz D., Pérez S., Gilboa-Garber N., Imberty A. // FEBS Lett. 2003. V. 555. № 2. P. 297-301.
13.	Mitchell E., Houles C., Sudakevitz D., Wimmerova M., Gautier C., Pérez S., Wu A.M., Gilboa-Garber N., Imberty A. // Nat. Struct. Biol. 2002. V. 9. № 12. P. 918-921.
14.	Winzer K., Falconer C., Garber N.C., Diggle S.P., Camara M., Williams P. // J. Bacteriol. 2000. V. 182. № 22. P. 64016411.
15.	Diggle S.P., Winzer K., Chhabra S.R., Worrall K.E., Cámara M., Williams P. // Mol. Microbiol. 2003. V. 50. № 1. P. 29-43.
16.	Bjarnsholt T., Tolker-Nielsen T., H0iby N., Givskov M. // Expert Rev. Mol. Med. 2010. V. 12. ell.
17.	Pessi G., Williams F., Hindle Z., Heurlier K., Holden M.T., Cámara M., Haas D., Williams P. // J. Bacteriol. 2001. V. 183. № 22. P. 6676-6683.
18.	Diggle S.P., Winzer K., Lazdunski A., Williams P., Camara M. // J. Bacteriol. 2002. V. 184. № 10. P. 2576-2586.
19.	Wu L., Estrada O., Zaborina O., Bains M., Shen L., Kohler J.E., Patel N., Musch M.W., Chang E.B., Fu Y.-X., et al. // Science. 2005. V. 309. № 5735. P. 774-777.
20.	Kipnis E., Sawa T., Wiener-Kronish J. // Médecine Mal. Infect. 2006. V. 36. № 2. P. 78-91.
21.	Alverdy J., Holbrook C., Rocha F., Seiden L., Wu R.L., Musch M., Chang E., Ohman D., Suh S. // Ann. Surg. 2000. V. 232. № 4. P. 480-489.
22.	Kohler J.E., Zaborina O., Wu L., Wang Y., Bethel C., Chen Y., Shapiro J., Turner J.R., Alverdy J.C. // Am. J. Physiol. Gastrointest. Liver Physiol. 2005. V. 288. № 5. P. G1048-1054.
23.	Zaborina O., Lepine F., Xiao G., Valuckaite V., Chen Y., Li T., Ciancio M., Zaborin A., Petrof E.O., Petroff E., et al. // PLoS Pathog. 2007. V. 3. № 3. . e35.
24.	Glick J., Garber N. // J. Gen. Microbiol. 1983. V. 129. № 10. P. 3085-3090.
25.	Tielker D., Hacker S., Loris R., Strathmann M., Wingen-der J., Wilhelm S., Rosenau F., Jaeger K.-E. // Microbiology. 2005. V. 151. Pt 5. P. 1313-1323.
26.	Funken H., Bartels K.-M., Wilhelm S., Brocker M., Bott M., Bains M., Hancock R.E.W., Rosenau F., Jaeger K.-E. // PLoS One. 2012. V. 7. № 10. . e46857.
27.	Fito-Boncompte L., Chapalain A., Bouffartigues E., Chaker H., Lesouhaitier O., Gicquel G., Bazire A., Madi A., Connil N., Véron W., et al. // Infect. Immun. 2011. V. 79. № 3. P. 1176-1186.
28.	Gilboa-Garber N., Sudakevitz D., Sheffi M., Sela R., Lev-ene C. // Glycoconj. J. 1994. V. 11. № 5. P. 414-417.
29.	Lanne B., Cîopraga J., Bergström J., Motas C., Karlsson K.A. // Glycoconj. J. 1994. V. 11. № 4. P. 292-298.
30.	Chen C.P., Song S.C., Gilboa-Garber N., Chang K.S., Wu A.M. // Glycobiology. 1998. V. 8. № 1. P. 7-16.
31.	Blanchard B., Nurisso A., Hollville E., Tétaud C., Wiels J., Pokorná M., Wimmerová M., Varrot A., Imberty A. // J. Mol. Biol. 2008. V. 383. № 4. P. 837-853.
32.	Perret S., Sabin C., Dumon C., Pokorná M., Gautier C., Galanina O., Ilia S., Bovin N., Nicaise M., Desmadril M., et al. // Biochem. J. 2005. V. 389. Pt 2. P. 325-332.
33.	Kirkeby S., Hansen A.K., d'Apice A., Moe D. // Microb. Pathog. 2006. V. 40. № 5. P. 191-197.
34.	Kirkeby S., Wimmerová M., Moe D., Hansen A.K. // Microbes Infect. 2007. V. 9. № 5. P. 566-573.
35.	Imberty A., Wimmerová M., Mitchell E.P., Gilboa-Garber N. // Microbes Infect. 2004. V. 6. № 2. P. 221-228.
36.	Wentworth J.S., Austin F.E., Garber N., Gilboa-Garber N., Paterson C.A., Doyle R.J. // Biofouling. 1991. V. 4. № 1-3. P. 99-104.
37.	Rebiere-Huët J., Di Martino P., Hulen C. // Can. J. Microbiol. 2004. V. 50. № 5. P. 303-312.
38.	Sonawane A., Jyot J., Ramphal R. // Infect. Immun. 2006. V. 74. № 12. P. 7035-7039.
39.	Chemani C., Imberty A., de Bentzmann S., Pierre M., Wimmerová M., Guery B.P., Faure K. // Infect. Immun. 2009. V. 77. № 5. P. 2065-2075.
40.	Boukerb A.M., Rousset A., Galanos N., Méar J.-B., Thépaut M., Grandjean T., Gillon E., Cecioni S., Abderrah-men C., Faure K., et al. // J. Med. Chem. 2014. V. 57. № 24. P. 10275-10289.
41.	Nosková L., Kubícková B., Vasková L., Bláhová B., Wimmerová M., Stiborová M., Hodek P. // Sensors. 2015. V. 15. № 1. P. 1945-1953.
42.	Eierhoff T., Bastian B., Thuenauer R., Madl J., Audfray A., Aigal S., Juillot S., Rydell G.E., Müller S., de Bentzmann S., et al. // Proc. Natl. Acad. Sci. USA. 2014. V. 111. № 35.
43.	Scharfman A., Arora S.K., Delmotte P., van Brussel E., Mazurier J., Ramphal R., Roussel P. // Infect. Immun. 2001. V. 69. № 9. P. 5243-5248.
44.	Hahn H.P. // Gene. 1997. V. 192. № 1. P. 99-108.
45.	Diggle S.P., Stacey R.E., Dodd C., Cámara M., Williams P., Winzer K. // Environ. Microbiol. 2006. V. 8. № 6. P. 10951104.
46.	Johansson E.M.V., Crusz S.A., Kolomiets E., Buts L., Kadam R.U., Cacciarini M., Bartels K.-M., Diggle S.P., Cámara M., Williams P., et al. // Chem. Biol. 2008. V. 15. № 12. P. 1249-1257.
47.	Ma L., Lu H., Sprinkle A., Parsek M.R., Wozniak D.J. // J. Bacteriol. 2007. V. 189. № 22. P. 8353-8356.
48.	Byrd M.S., Sadovskaya I., Vinogradov E., Lu H., Sprinkle A.B., Richardson S.H., Ma L., Ralston B., Parsek M.R., Anderson E.M., et al. // Mol. Microbiol. 2009. V. 73. № 4. P. 622-638.
49.	Ma L., Conover M., Lu H., Parsek M.R., Bayles K., Wozniak D.J. // PLoS Pathog. 2009. V. 5. № 3. e1000354.
50.	Bajolet-Laudinat O., Girod-De Bentzmann S.G., Tournier J.M., Madoulet C., Plotkowski M.C., Chippaux C., Puchelle E. // Infect. Immun. 1994. V. 62. № 10. P. 4481-4487.
51.	Mewe M., Tielker D., Schönberg R., Schachner M., Jaeger K.-E., Schumacher U. // J. Laryngol. Otol. 2005. V. 119. № 8. P. 595-599.
52.	Gustke H., Kleene R., Loers G., Nehmann N., Jaehne M., Bartels K.-M., Jaeger K.-E., Schachner M., Schumacher U. // Eur. J. Clin. Microbiol. Infect. Dis. 2012. V. 31. № 2.
Schumacher U. // Am. J. Respir. Crit. Care Med. 1997. V. 155. № 6. P. 2102-2104.
54.	Adam E.C., Schumacher D.U., Schumacher U. // J. Laryngol. Otol. 1997. V. 111. № 8. P. 760-762.
55.	Laughlin R.S., Musch M.W., Hollbrook C.J., Rocha F.M., Chang E.B., Alverdy J.C. // Ann. Surg. 2000. V. 232. № 1. P. 133-142.
56.	Wu L., Holbrook C., Zaborina O., Ploplys E., Rocha F., Pelham D., Chang E., Musch M., Alverdy J. // Ann. Surg. 2003. V. 238. № 5. P. 754-764.
57.	Zinger-Yosovich K.D., Gilboa-Garber N. // J. Agric. Food Chem. 2009. V. 57. № 15. P. 6908-6913.
58.	Nurisso A., Blanchard B., Audfray A., Rydner L., Oscar-son S., Varrot A., Imberty A. // J. Biol. Chem. 2010. V. 285. № 26. P. 20316-20327.
59.	Kadam R.U., Bergmann M., Hurley M., Garg D., Cacciarini M., Swiderska M.A., Nativi C., Sattler M., Smyth A.R., Williams P., et al. // Angew. Chem. Int. Ed. Engl. 2011. V. 50. № 45. P. 10631-10635.
60.	Garber N., Guempel U., Belz A., Gilboa-Garber N., Doyle R.J. // Biochim. Biophys. Acta. 1992. V. 1116. № 3. P. 331-333.
61.	Stoitsova S.R., Boteva R.N., Doyle R. // Biochim. Biophys. Acta - Gen. Subj. 2003. V. 1619. № 2. P. 213-219.
62.	Boteva R.N., Bogoeva V.P., Stoitsova S.R. // Biochim. Biophys. Acta. 2005. V. 1747. № 2. P. 143-149.
63.	Loris R., Tielker D., Jaeger K.-E., Wyns L. // J. Mol. Biol. 2003. V. 331. № 4. P. 861-870.
64.	Garber N., Guempel U., Gilboa-Garber N., Doyle R. // FEMS Microbiol. Lett. 1987. V. 48. № 3. P. 331-334.
65.	Sabin C., Mitchell E.P., Pokorna M., Gautier C., Utille J.-P., Wimmerova M., Imberty A. // FEBS Lett. 2006. V. 580. № 3. P. 982-987.
66.	Lesman-Movshovich E., Lerrer B., Gilboa-Garber N. // Can. J. Microbiol. 2003. V. 49. № 3. P. 230-235.
67.	Wu A.M., Wu J.H., Singh T., Liu J.-H., Tsai M.-S., Gil-boa-Garber N. // Biochimie. 2006. V. 88. № 10. P. 1479-1492.
68.	Kadam R.U., Garg D., Schwartz J., Visini R., Sattler M., Stocker A., Darbre T., Reymond J.-L. // ACS Chem. Biol. 2013. V. 8. № 9. P. 1925-1930.
69.	Rodrigue J., Ganne G., Blanchard B., Saucier C., Giguère D., Shiao T.C., Varrot A., Imberty A., Roy R. // Org. Biomol. Chem. 2013. V. 11. № 40. P. 6906-6918.
70.	Cecioni S., Praly J.-P., Matthews S.E., Wimmerova M., Imberty A., Vidal S. // Chemistry. 2012. V. 18. № 20. P. 6250-6263.
A.G.,	Tsvetkov Y.E., Krylov V.B., Imberty A., Nifantiev N.E., Vidal S. // Chemistry. 2013. V. 19. № 28. P. 9272-9285.
72.	Marotte K., Sabin C., Préville C., Moumé-Pymbock M., Wimmerova M., Mitchell E.P., Imberty A., Roy R. // ChemMedChem. 2007. V. 2. № 9. P. 1328-1338.
73.	Andreini M., Anderluh M., Audfray A., Bernardi A., Im-berty A. // Carbohydr. Res. 2010. V. 345. № 10. P. 1400-1407.
B.,	Möller H.M., Imberty A., Exner T.E., Titz A. // ACS Chem. Biol. 2013. V. 8. № 8. P. 1775-1784.
75.	Dam T.K., Brewer C.F. // Chem. Rev. 2002. V. 102. № 2. P. 387-429.
76.	Wittmann V., Pieters R.J. // Chem. Soc. Rev. 2013. V. 42. № 10. P. 4492-4503.
77.	Dam T.K., Brewer C.F. // Adv. Carbohydr. Chem. Biochem. 2010. V. 63. № 10. P. 139-164.
78.	Imberty A., Chabre Y.M., Roy R. // Chemistry. 2008. V. 14. № 25. P. 7490-7499.
79.	Smadhi M., de Bentzmann S., Imberty A., Gingras M., Abderrahim R., Goekjian P.G. // Beilstein J. Org. Chem. 2014. V. 10. P. 1981-1990.
80.	Cecioni S., Lalor R., Blanchard B., Praly J.-P., Imberty A., Matthews S.E., Vidal S. // Chemistry. 2009. V. 15. № 47. P. 13232-13240.
81.	Cecioni S., Faure S., Darbost U., Bonnamour I., Parrot-Lopez H., Roy O., Taillefumier C., Wimmerova M., Praly J.-P., Imberty A., et al. // Chemistry. 2011. V. 17. № 7. P. 2146-2159.
82.	Soomro Z.H., Cecioni S., Blanchard H., Praly J.-P., Imberty A., Vidal S., Matthews S.E. // Org. Biomol. Chem. 2011. V. 9. № 19. P. 6587-6597.
83.	Cecioni S., Oerthel V., Iehl J., Holler M., Goyard D., Praly J.-P., Imberty A., Nierengarten J.-F., Vidal S. // Chemistry. 2011. V. 17. № 11. P. 3252-3261.
84.	Otsuka I., Blanchard B., Borsali R., Imberty A., Kakuchi T. // ChemBioChem. 2010. V. 11. № 17. P. 2399-2408.
85.	Reynolds M., Marradi M., Imberty A., Penadés S., Pérez S. // Chemistry. 2012. V. 18. № 14. P. 4264-4273.
86.	Kadam R.U., Bergmann M., Garg D., Gabrieli G., Stocker A., Darbre T., Reymond J.-L. // Chemistry. 2013. V. 19. № 50. P. 17054-17063.
87.	Chabre Y.M., Giguère D., Blanchard B., Rodrigue J., Ro-cheleau S., Neault M., Rauthu S., Papadopoulos A., Arnold A.A., Imberty A., et al. // Chemistry. 2011. V. 17. № 23.
88.	Gerland B., Goudot A., Ligeour C., Pourceau G., Meyer A., Vidal S., Gehin T., Vidal O., Souteyrand E., Vasseur J.J., et al. // Bioconjug. Chem. 2014. V. 25. P. 379-392.
89.	Pertici F., Pieters R.J. // Chem. Commun. (Camb.). 2012. V. 48. № 33. P. 4008-4010.
90.	Pertici F., de Mol N.J., Kemmink J., Pieters R.J. // Chemistry. 2013. V. 19. № 50. P. 16923-16927.
91.	Novoa A., Eierhoff T., Topin J., Varrot A., Barluenga S., Imberty A., Römer W., Winssinger N. // Angew. Chem. Int. Ed. Engl. 2014. V. 53. № 34. P. 8885-8889.
92.	Morvan F., Meyer A., Jochum A., Sabin C., Chevolot Y., Imberty A., Praly J.-P., Vasseur J.-J., Souteyrand E., Vidal S. // Bioconjug. Chem. 2007. V. 18. № 5. P. 1637-1643.
93.	Berthet N., Thomas B., Bossu I., Dufour E., Gillon E., Garcia J., Spinelli N., Imberty A., Dumy P., Renaudet O. // Bioconjug. Chem. 2013. V. 24. № 9. P. 1598-1611.
94.	Kolomiets E., Swiderska M.A, Kadam R.U., Johansson E.M.V., Jaeger K.-E., Darbre T., Reymond J.-L. // ChemMedChem. 2009. V. 4. № 4. P. 562-569.
95.	Johansson E.M.V, Kadam R.U., Rispoli G., Crusz S. A., Bartels K.-M., Diggle S.P., Cámara M., Williams P., Jaeger K.-E., Darbre T., et al. // Med. Chem. Commun. 2011. V. 2. № 5. P. 418-420.
96.	Marotte K., Préville C., Sabin C., Moumé-Pymbock M., Imberty A., Roy R. // Org. Biomol. Chem. 2007. V. 5. № 18. P. 2953-2961.
97.	Lerrer B., Gilboa-Garber N. // FEMS Immunol. Med. Microbiol. 2001. V. 32. № 1. P. 33-36.
98.	Lerrer B., Gilboa-Garber N. // Electrophoresis. 2002. V. 23. № 1. P. 8-14.
99.	Gilboa-Garber N., Zinger-Yosovich K., Lerrer B. // J. ApiProduct ApiMedical Sci. 2009. V. 1. № 3. P. 82-89.
100.	Zinger-Yosovich K.D., Iluz D., Sudakevitz D., Gil-boa-Garber N. // J. Dairy Sci. 2010. V. 93. № 2. P. 473-482.
101.	Rachmaninov O., Zinger-Yosovich K.D., Gilboa-Garber N. // Nutr. J. 2012. V. 11. № 1. P. 10.
102.	Grishin A., Karyagina A.S., Tiganova I.G., Dobrynina O.Y., Bolshakova T.N., Boksha I.S., Alexeyeva N.V., Stepano-va T.V., Lunin V.G., Chuchalin A.G., et al. // Int. J. Antimi-crob. Agents. 2013. V. 42. № 5. P. 471-472.
103.	Steuer M.K., Herbst H., Beuth J., Steuer M., Pulverer G., Matthias R. // Oto-Rhino-Laryngologia Nov. 1993. V. 3. № 1. P. 19-25.
104.	von Bismarck P., Schneppenheim R., Schumacher U. // Klin. Pädiatrie. 2001. V. 213. № 5. P. 285-287.
105.	Hauber H.-P., Schulz M., Pforte A., Mack D., Zabel P., Schumacher U. // Int. J. Med. Sci. 2008. V. 5. № 6. P. 371-376.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V.